HomeCompareKKPCF vs PFE

KKPCF vs PFE: Dividend Comparison 2026

KKPCF yields 4.58% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KKPCF wins by $10.9K in total portfolio value
10 years
KKPCF
KKPCF
● Live price
4.58%
Share price
$26.00
Annual div
$1.19
5Y div CAGR
25.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$60.4K
Annual income
$10,901.81
Full KKPCF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — KKPCF vs PFE

📍 KKPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKKPCFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KKPCF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KKPCF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KKPCF
Annual income on $10K today (after 15% tax)
$389.04/yr
After 10yr DRIP, annual income (after tax)
$9,266.54/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $13,053.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KKPCF + PFE for your $10,000?

KKPCF: 50%PFE: 50%
100% PFE50/50100% KKPCF
Portfolio after 10yr
$55.0K
Annual income
$18,580.26/yr
Blended yield
33.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

KKPCF
No analyst data
Altman Z
4.9
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KKPCF buys
0
PFE buys
0
No recent congressional trades found for KKPCF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKKPCFPFE
Forward yield4.58%6.13%
Annual dividend / share$1.19$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR25.2%13.2%
Portfolio after 10y$60.4K$49.6K
Annual income after 10y$10,901.81$26,258.71
Total dividends collected$34.9K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KKPCF vs PFE ($10,000, DRIP)

YearKKPCF PortfolioKKPCF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,273$573.03$9,153$693.39+$2.1KKKPCF
2$12,818$755.86$8,593$849.25+$4.2KKKPCF
3$14,721$1,005.63$8,336$1,066.78+$6.4KKKPCF
4$17,103$1,351.37$8,437$1,384.80+$8.7KKKPCF
5$20,137$1,837.07$9,013$1,875.40+$11.1KKKPCF
6$24,077$2,530.90$10,306$2,680.72+$13.8KKKPCF
7$29,304$3,540.89$12,820$4,101.38+$16.5KKKPCF
8$36,398$5,042.49$17,673$6,826.70+$18.7KKKPCF
9$46,274$7,328.49$27,543$12,591.86+$18.7KKKPCF
10$60,415$10,901.81$49,560$26,258.71+$10.9KKKPCF

KKPCF vs PFE: Complete Analysis 2026

KKPCFStock

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Full KKPCF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this KKPCF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KKPCF vs SCHDKKPCF vs JEPIKKPCF vs OKKPCF vs KOKKPCF vs MAINKKPCF vs JNJKKPCF vs MRKKKPCF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.